Experimental drug ALMB-0166 tested in spinal cord injury patients
NCT ID NCT05524103
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a single dose of an experimental drug called ALMB-0166 in 24 people with acute spinal cord injury. The main goal was to check safety and how the drug moves through the body. Participants had moderate to severe injuries and were scheduled for surgery within 72 hours. Results will help decide if further studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALMB-0166 (an experimental drug given as a single injection)
What this could lead to
If this drug is safe and shows promise, it could point toward a treatment that helps limit damage after a spinal cord injury.
What could go wrong
This is a very early phase 1 trial with only 24 participants, focused on safety, not effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE SPINAL CORD INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, China
-
Peking University Third Hospital Medical Science Research Ethic Committee
Beijing, Beijing Municipality, 100191, China